AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02012088
Drug: RCOMP
RxNorm normalized name: Sarcomphalus joazeiro bark extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1: Rituximab 375 mg/m2; Myocet® 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles
Trial: NCT01479946
Drug: Electrochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bleomycin together with electroporation
Trial: NCT01495520
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: os, pill, b.i.d., 30 days
Trial: NCT00513955
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00513955
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00513955
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02794389
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02177513
Drug: Placebo + Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette followed by smoking or inhaling (after vaporization) the equivalent of one placebo (0.001% THC) cigarette.
Trial: NCT02177513
Drug: 6.9% cannabis oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will consume a brownie containing the equivalent of one active (6.91% THC) cannabis cigarette.
Trial: NCT00739466
Drug: Saline infusion (placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV saline infusion during the index procedure (coronary stent implantation) over 2 hours
Trial: NCT01930552
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:Solution for infusion Route of administration: Intravenous
Trial: NCT00539929
Drug: E6201 0.005%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00539929
Drug: E6201 0.01%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00539929
Drug: E6201 0.03%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00539929
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02204852
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01669213
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: before 5 minutes spinal anesthesia, injection of normal saline 5 ml
Trial: NCT02064608
Drug: AZD2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mTOR inhibitor
Trial: NCT01071616
Drug: Cannabis Cigarette
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02643823
Drug: DMARDs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated by conventional drugs (DMARDs) for alleviating disease.
Trial: NCT02666794
Drug: Epidural sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mcg
Trial: NCT02666794
Drug: Intrathecal sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mcg
Trial: NCT02155530
Drug: pravastatin 20 mg
RxNorm normalized name: pravastatin 20 mg oral tablet
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention description : homogenous neointimal pattern at baseline OCT and randomized to pravastatin 20 mg group
Trial: NCT00261742
Drug: Penicillin versus cefuroxim per os
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01638559
Drug: Immunosuppression withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will undergo gradual ISW in no less than 36 weeks and no more than 52 weeks with frequent monitoring of liver tests. All participants will be followed for 48 months ensuring a minimum of 36 months of follow-up after successful ISW.
Trial: NCT00686556
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg
Trial: NCT04689971
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin, pregabalin, or amitriptyline
Trial: NCT02062203
Drug: AKB-6548 (therapeutic dose)
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of AKB-6548 at a therapeutic dose level
Trial: NCT02062203
Drug: AKB-6548 (supratherapeutic dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of AKB-6548 at a supratherapeutic dose level
Trial: NCT02062203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of placebo
Trial: NCT01704703
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 180 mg/m2 day 1 i.v. 30-90 min Folinic acid 400 mg/ m2 day 1 i.v. 120 min 5-FU 400 mg/ m2 day 1 Bolus 5-FU 2.400 mg/ m2 day 1 i.v. 46 hours
Trial: NCT00793793
Drug: BI201335
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
Trial: NCT04151849
Drug: GLP-1 receptor agonist
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with GLP-1 agonist for up to 1 year.
Trial: NCT02881528
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid formula of placebo administered by oral syringe in an equivalent volume to a metformin dose of 10mg/kg body weight once daily for 2 weeks, then to 10mg/Kg twice daily (maximum 500mg twice daily) for a further two weeks during the first month, increasing to 20mg/kg body weight twice daily (maximum 1000mg twice daily) thereafter.
Trial: NCT00793793
Drug: BI201335
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient to receive 240mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
Trial: NCT00793793
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00979849
Drug: AZD8683
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for nebulisation, inhaled. Each subject will receive a single-dose of AZD8683 or placebo. Starting dose 1 ug (lung deposited dose) with up to 8 dose escalation not exceeding AstraZeneca pre-defined exposure limits.
Trial: NCT00979849
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for nebulisation, inhaled
Trial: NCT00127309
Drug: Glutathione
RxNorm normalized name: Glutathione
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03562416
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00106574
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv every 4 weeks
Trial: NCT01286584
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lactose filler in capsules identical to the varenicline capsules one 0.5mg capsule for 3 days one 0.5mg capsule twice daily for 4 days one 1.0mg capsule twice daily until end of treatment (12weeks of medication)
Trial: NCT02770521
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT02770521
Drug: LY900014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT00238368
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00238368
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02159807
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 micrograms routinely administered in combination in the spinal anesthetic
Trial: NCT01350115
Drug: LDE225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: supplied as 100 mg capsules
Trial: NCT01350115
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: supplied in capsules
Trial: NCT01552902
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral dosing in the AM for 6 weeks
Trial: NCT03645304
Drug: 0.9% saline group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the control group, an elastomeric pump filled with filled with 100ml of 0.9% saline .
Trial: NCT01113034
Drug: DAS181 dry powder, formulation F02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg delivered dose DAS181 in clear HPMC #3 Capsules
Trial: NCT01113034
Drug: Respitose ML006 (DMV-Fonterra)
RxNorm normalized name: ZINC OXIDE 17.5 g in 100 g TOPICAL SPRAY [doTERRA sun]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose monohydrate
Trial: NCT00006268
Drug: isolated perfusion
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00783081
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo BID for 26 weeks.
Trial: NCT04031872
Drug: LY3200882
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with LY3200882 and capecitabine
Trial: NCT01179061
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As per apelin arm, however we will use a saline placebo infusion. All other aspects will remain the same.
Trial: NCT02479789
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03804671
Drug: BI 730357 mixed with [C-14] BI 730357 BS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dose
Trial: NCT01571063
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Tbl. p.o.
Trial: NCT03143998
Drug: MK-5172A
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.
Trial: NCT00556179
Drug: Lactoserum (Dermacyd Femina®)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once a day during three months
Trial: NCT02571660
Drug: GINA treatment fot asthma +vit.D low supplementation dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of 400 IU of vitamin D3 every 24 hours for 1 year + the standard treatment for asthma,
Trial: NCT02571660
Drug: GINA treatment fot asthma +vit.D high supplementation dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of 1600 IU of vitamin D3 be allocated each 24 hours for 1 year + standard treatment for asthma
Trial: NCT01066351
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients were assigned to receive normal saline same volume at 3 day before cardiac surgery and in the morning before cardiac surgery.
Trial: NCT02194322
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01688739
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection or intravenous injection
Trial: NCT00996801
Drug: MK-5442
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-5442 tablets (randomized to a dose of 5, 7.5, 10 or 15 mg) taken orally, once-daily, for 12 months
Trial: NCT00996801
Drug: Placebo to MK-5442
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to MK-5442 taken orally, once-daily, for 12 months
Trial: NCT00996801
Drug: Placebo to Alendronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to alendronate once-weekly for 12 months
Trial: NCT02335632
Drug: Probiotics (Lacidofil®)
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days of cultured Lactobacillus rhamnosus R0011/acidophilus R0052 (120 mg/day)
Trial: NCT02335632
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For probiotics
Trial: NCT01973608
Drug: MSB0010445 (0.3 milligram per kilogram [mg/kg])
RxNorm normalized name: ALLOGENIC ADIPOSE DERIVED MESENCHYMAL STEM CELLS (MSCS) EXOSOMES 15 mg in 3 mL TOPICAL POWDER, FOR SOLUTION [Biogram Anti Hair Loss Ampoule]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSB0010445 will be administered at a single dose of 0.3 mg/kg as intravenous (IV) infusion over approximately 1 hour every 3 weeks (q3w) for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of Stereotactic Body Radiation Therapy (SBRT) to the targeted reference lesion.
Trial: NCT01973608
Drug: MSB0010445 (1.0 mg/kg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSB0010445 will be administered at a single dose of 1.0 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
Trial: NCT01973608
Drug: MSB0010445 (1.8 mg/kg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSB0010445 will be administered at a single dose of 1.8 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
Trial: NCT01973608
Drug: MSB0010445 (2.4 mg/kg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSB0010445 will be administered at a single dose of 2.4 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
Trial: NCT03917069
Drug: Chemotherapeutic Combinations
RxNorm normalized name: ANTIBIOTICS AND CHEMOTHERAPEUTICS, COMBINATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-paclitaxel 260mg/m2 d1+Carboplatin AUC=5 d1+ endostatin 15mg d1-14，q28d
Trial: NCT03917069
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paclitaxel 175 mg/m2 d1+Carboplatin AUC=5 d1, q21d
Trial: NCT00002514
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002514
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002514
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002514
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02408692
Drug: ECx1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the first treatment visit, all women will be given the study drug (1.5 mg of levonorgestrel) and several blood samples will be taken over 2.5 hours). After this visit, women with a BMI of \<25 kg/m2 will have completed study participation.
Trial: NCT01976858
Drug: PEX168
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A injection administered subcutaneously
Trial: NCT04790487
Drug: CPM
RxNorm normalized name: CPM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one spray dose (\~100 µL of the solution containing 1.25 mg CPM) per nostril twice a day
Trial: NCT04790487
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline
Trial: NCT04792333
Drug: firibastat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 500 mg administration on Day 1
Trial: NCT00673881
Drug: choline fenofibrate
RxNorm normalized name: Choline Fenofibrate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 135 mg choline fenofibrate daily(oral, capsule)
Trial: NCT02642146
Drug: Calcium Channel Blockers
RxNorm normalized name: CALCIUM CHANNEL BLOCKERS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02642146
Drug: Phosphodiesterase Inhibitors
RxNorm normalized name: Phosphodiesterase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02642146
Drug: Endothelin receptor blocker
RxNorm normalized name: endothelial growth factor A, vascular
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02642146
Drug: Prostanoids
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02642146
Drug: Other vasodilator
RxNorm normalized name: Other vasodilators used in cardiac diseases
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03545997
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol 350mg The capsules will be presented in box of 95 capsules packaged in unit blister
Trial: NCT02408692
Drug: ECx2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the first treatment visit, all women will be given the study drug (1.5 mg of levonorgestrel) and several blood samples will be taken over 2.5 hours). For women with a BMI of 30kg/m2 and greater, one additional visit will be required and study drug (3 mg of levonorgestrel) will be given and several blood samples will be taken over 2.5 hours)
Trial: NCT03283150
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanyl will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the bispectral index (BIS) values to normalize to awake level for the MER.
Trial: NCT00360347
Drug: C.E.R.A.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00542191
Drug: Doxorubicin / Cyclophosphamide / Paclitaxel / Carboplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOXORUBICIN 24mg/m2 IV plus CYCLOPHOSPHAMIDE 60mg/m2 PO weekly x 12 successive weeks followed by PACLITAXEL 80mg/m2 IV over 1 hour plus CARBOPLATIN AUC 2 IV weekly x 12 successive weeks
Trial: NCT00539617
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 IV once every 2 weeks for 16 weeks
Trial: NCT05918627
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: capsule; Route of administration: oral
Trial: NCT03772418
Drug: Cream Base
RxNorm normalized name: Cream Base
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The formulated dosage form without ginkgo biloba or pomegranate will be applied to the 30 aging people who are suffering from wrinkles in the skin male and female. Typically, will be applied on two groups, one man (Group 0a) and one woman were (Group 0b) which they will be used plain cream.
Trial: NCT01616485
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo capsules for TA-1790 100 mg capsules
Trial: NCT01743404
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic Inflaminat 500 mg tablet
Trial: NCT00693004
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000120
Drug: Erythromycin Ointment
RxNorm normalized name: Erythromycin Ointment
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01533922
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo matching tiotropium + olodaterol FDC
Trial: NCT00784732
Drug: QAV680
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00675896
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet at HS for 2 days then 3 tablets at HS for 2 weeks
Trial: NCT04292990
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patch releasing drug at the rate of 25 µg/hour, increasing by 25 µg/hour increments to maintain the NRS score≤3 after the frst 24 hours according to no change in pain control. The maximum dose allowed in this study is 300 µg/hour.
Trial: NCT03713190
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A substance without specific pharmacology principles
Trial: NCT03242252
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet (identical to sotagliflozin 200 mg in appearance), orally once daily.~Route of administration: Oral
Trial: NCT00993499
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation (19-40 patients): low or high dose oral + 12 addit. pat. at MTD, until progression or undue AEs
Trial: NCT02192229
Drug: Placebo (to mimic Biodal 50,000 IU)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Tablet will be manufactured in a pharmaceutical factory to be identical to vitamin D3 Tablet in color, shape, size, and packaging